written by reader I made over 200%, XENT

By climmm, March 13, 2021

After conducting the research, I invested in and made over 200% on (XTLB) & (EYES), short % of float has been reduced to less than 1% of outstanding shares short currently.

Now investing in ( XENT ), has a short % of float of 6x larger (6.25%), total of 1,050,000 shares short, so may see an even lager gain.

Ears, Nose, Throat Devices Market to reach $26BB, with cumulative impact of COVID-19 SARS CoV2 variants, bio-absorbable therapies such as Propel & Sinuva fastest growing segment.


( XENT ) capturing 5% of market realize $1.3BB in revenues/ 32MM Shares = 40$ per share in Revenue, at comp. 10X Sales= $200 per share

( XENT ) Intersect ENT Inc .

– Positive 10 day & 50 day Moving Average
– Current Assets to Liabilities ratio attractive
– Enterprise Value is undervalued compared to peer group
– 5 Day Rounding Bottom chart + ( Cup & Handle )
– Moving Average Convergence Divergence crossing higher.

Christopher Michael Lim, MSc . Health Sciences
Western University Medical

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

1 Comment
Inline Feedbacks
View all comments
March 14, 2021 3:31 pm

I have been a member for a few years anyone been oxforyt portfolios or Cabot stock advisor or mf I have lifetime membership will give password and username if I think you solid. I am, and would like to get info from day fintech but that sSid he has a stock
You know what I mean?

Add a Topic
Add a Topic
Add a Topic
👍 7